These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 34669065)

  • 1. Free fatty acid receptor 1: a ray of hope in the therapy of type 2 diabetes mellitus.
    Arora A; Behl T; Sehgal A; Singh S; Sharma N; Chigurupati S; Kaur R; Bhatia S; Al-Harrasi A; Vargas-De-La-Cruz C; Bungau S
    Inflammopharmacology; 2021 Dec; 29(6):1625-1639. PubMed ID: 34669065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent Updates on Free Fatty Acid Receptor 1 (GPR-40) Agonists for the Treatment of Type 2 Diabetes Mellitus.
    Rani L; Grewal AS; Sharma N; Singh S
    Mini Rev Med Chem; 2021; 21(4):426-470. PubMed ID: 33100202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current status of GPR40/FFAR1 modulators in medicinal chemistry (2016-2019): a patent review.
    Li Z; Zhou Z; Zhang L
    Expert Opin Ther Pat; 2020 Jan; 30(1):27-38. PubMed ID: 31771391
    [No Abstract]   [Full Text] [Related]  

  • 4. FFAR1/GPR40: One target, different binding sites, many agonists, no drugs, but a continuous and unprofitable tug-of-war between ligand lipophilicity, activity, and toxicity.
    Governa P; Caroleo MC; Carullo G; Aiello F; Cione E; Manetti F
    Bioorg Med Chem Lett; 2021 Jun; 41():127969. PubMed ID: 33771587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel antidiabetic drug, fasiglifam/TAK-875, acts as an ago-allosteric modulator of FFAR1.
    Yabuki C; Komatsu H; Tsujihata Y; Maeda R; Ito R; Matsuda-Nagasumi K; Sakuma K; Miyawaki K; Kikuchi N; Takeuchi K; Habata Y; Mori M
    PLoS One; 2013; 8(10):e76280. PubMed ID: 24130766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus: Benefits and Challenges.
    Mohammad S
    Curr Drug Targets; 2016; 17(11):1292-300. PubMed ID: 26648068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Free Fatty Acid Receptor 1 (FFAR1) as an Emerging Therapeutic Target for Type 2 Diabetes Mellitus: Recent Progress and Prevailing Challenges.
    Li Z; Xu X; Huang W; Qian H
    Med Res Rev; 2018 Mar; 38(2):381-425. PubMed ID: 28328012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthetic GPR40/FFAR1 agonists: An exhaustive survey on the most recent chemical classes and their structure-activity relationships.
    Paul A; Nahar S; Nahata P; Sarkar A; Maji A; Samanta A; Karmakar S; Maity TK
    Eur J Med Chem; 2024 Jan; 264():115990. PubMed ID: 38039791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CPL207280, a Novel G Protein-Coupled Receptor 40/Free Fatty Acid Receptor 1-Specific Agonist, Shows a Favorable Safety Profile and Exerts Antidiabetic Effects in Type 2 Diabetic Animals.
    Bazydlo-Guzenda K; Buda P; Matloka M; Mach M; Stelmach F; Dzida R; Smuga D; Hucz-Kalitowska J; Teska-Kaminska M; Vialichka V; Dubiel K; Kaminska B; Wieczorek M; Pieczykolan J
    Mol Pharmacol; 2021 Oct; 100(4):335-347. PubMed ID: 34349026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and biological evaluations of phenylpropiolic acid derivatives as novel GPR40 agonists.
    Jiang XW; Jiang BE; Liu H; Liu ZT; Hu LL; Liu M; Lu W; Zhang HK
    Eur J Med Chem; 2018 Oct; 158():123-133. PubMed ID: 30212763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GPR40 agonists for the treatment of type 2 diabetes mellitus: The biological characteristics and the chemical space.
    Chen C; Li H; Long YQ
    Bioorg Med Chem Lett; 2016 Dec; 26(23):5603-5612. PubMed ID: 27825762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulating GPR40: therapeutic promise and potential in diabetes.
    Poitout V; Lin DC
    Drug Discov Today; 2013 Dec; 18(23-24):1301-8. PubMed ID: 24051395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GPR120 agonists for the treatment of diabetes: a patent review (2014 present).
    Zhang X; Macielag MJ
    Expert Opin Ther Pat; 2020 Oct; 30(10):729-742. PubMed ID: 32799609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An updated patent review of GPR40/ FFAR1 modulators (2020 - present).
    Ren Q; Fan Y; Yang L; Shan M; Shi W; Qian H
    Expert Opin Ther Pat; 2023; 33(9):565-577. PubMed ID: 37947382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Free fatty acid receptor agonists for the treatment of type 2 diabetes: drugs in preclinical to phase II clinical development.
    Li Z; Qiu Q; Geng X; Yang J; Huang W; Qian H
    Expert Opin Investig Drugs; 2016 Aug; 25(8):871-90. PubMed ID: 27171154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Free fatty acid receptor 1 as a novel therapeutic target for type 2 diabetes mellitus-current status.
    Eleazu C; Charles A; Eleazu K; Achi N
    Chem Biol Interact; 2018 Jun; 289():32-39. PubMed ID: 29704509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats.
    Tsujihata Y; Ito R; Suzuki M; Harada A; Negoro N; Yasuma T; Momose Y; Takeuchi K
    J Pharmacol Exp Ther; 2011 Oct; 339(1):228-37. PubMed ID: 21752941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A FFAR1 full agonist restores islet function in models of impaired glucose-stimulated insulin secretion and diabetic non-human primates.
    Rady B; Liu J; Huang H; Bakaj I; Qi J; Lee SP; Martin T; Norquay L; Player M; Pocai A
    Front Endocrinol (Lausanne); 2022; 13():1061688. PubMed ID: 36482991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of Potent and Orally Bioavailable GPR40 Full Agonists Bearing Thiophen-2-ylpropanoic Acid Scaffold.
    Li H; Huang Q; Chen C; Xu B; Wang HY; Long YQ
    J Med Chem; 2017 Apr; 60(7):2697-2717. PubMed ID: 28277660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470).
    Hamdouchi C; Kahl SD; Patel Lewis A; Cardona GR; Zink RW; Chen K; Eessalu TE; Ficorilli JV; Marcelo MC; Otto KA; Wilbur KL; Lineswala JP; Piper JL; Coffey DS; Sweetana SA; Haas JV; Brooks DA; Pratt EJ; Belin RM; Deeg MA; Ma X; Cannady EA; Johnson JT; Yumibe NP; Chen Q; Maiti P; Montrose-Rafizadeh C; Chen Y; Reifel Miller A
    J Med Chem; 2016 Dec; 59(24):10891-10916. PubMed ID: 27749056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.